---
title: "Genfit SA Highlights Pipeline Progress and Commercial Success in Latest Corporate Presentation"
description: "Genfit SA has updated its commercial, clinical, and research activities, reporting strong sales of Iqirvo® for primary biliary cholangitis. The company is advancing its investigational candidate G1090"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275149217.md"
published_at: "2026-02-06T15:53:12.000Z"
---

# Genfit SA Highlights Pipeline Progress and Commercial Success in Latest Corporate Presentation

> Genfit SA has updated its commercial, clinical, and research activities, reporting strong sales of Iqirvo® for primary biliary cholangitis. The company is advancing its investigational candidate G1090N for acute-on-chronic liver failure into Phase 2 studies and anticipates Phase 2 trials for its oncology program GNS561 for cholangiocarcinoma in 2026. Genfit has a cash position of €119 million as of Q3 2025, with a projected runway extending beyond 2028. The full presentation is available via the provided link.

Genfit SA has provided an update on its commercial, clinical, and research activities. The company reported strong commercial sales of Iqirvo® in primary biliary cholangitis (PBC), with continued updates expected from Ipsen, its commercialization partner. Genfit highlighted progress on its investigational candidate G1090N for acute-on-chronic liver failure (ACLF), noting its safety profile and anti-inflammatory activity and plans to advance into Phase 2 proof-of-concept studies. The company’s oncology program, GNS561 for cholangiocarcinoma (CCA), has demonstrated a favorable safety profile and early antitumor activity, with Phase 2 trials anticipated to begin in the second half of 2026. Additional programs in ACLF and UCD/OA are progressing through preclinical and early clinical stages. Genfit reported a cash position of €119 million at the end of Q3 2025 and projects a cash runway extending beyond 2028. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GNFT.US - Genfit](https://longbridge.com/en/quote/GNFT.US.md)
- [GNFTY.US - GENFIT SPON ADS EACH REP 1 ORD SHS](https://longbridge.com/en/quote/GNFTY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 02:00 ETMammotome führt das erste MR-Vakuum-unterstützte Brustbiopsiesystem für den Innenraum ein | Mammotome, a Danaher company, has announced the launch of the Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy Sys | [Link](https://longbridge.com/en/news/276203846.md) |
| Genfit SA Publishes Corporate Presentation Highlighting Pipeline Progress in Rare Liver Diseases and Updates on Iqirvo® Commercialization | Genfit SA has published a corporate presentation outlining its progress in developing treatments for rare liver diseases | [Link](https://longbridge.com/en/news/260932002.md) |
| Eqva - Invitation to presentation of fourth quarter results 2025 | 20 February: Eqva ASA will release its fourth quarter results 2025 on Tuesday24February 2026. The presentation will be a | [Link](https://longbridge.com/en/news/276436557.md) |
| QBE Releases Investor Presentation on 2025 Full-Year Results | QBE Insurance Group Limited has released an investor presentation detailing its financial and operational results for th | [Link](https://longbridge.com/en/news/276376708.md) |
| Elliott Sends Letter and Presentation to Board of Directors of Norwegian Cruise Line Holdings Ltd. | Elliott Investment Management has sent a letter and presentation to the Board of Directors of Norwegian Cruise Line Hold | [Link](https://longbridge.com/en/news/276134405.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.